Why Does Menopause Cause Intimate Health Problems?
Declining estrogen during menopause causes genitourinary syndrome of menopause (GSM), a progressive condition affecting perimenopausal and postmenopausal women. This condition causes vaginal dryness, irritation, burning, itching, abnormal discharge, painful intercourse, and urinary symptoms including urgency, frequency, incontinence, and recurrent urinary tract infections. GSM is a spectrum of changes in the urogenital tissues driven by a hypoestrogenic state, and it does not resolve on its own.
Dr. Kumar’s Take
Genitourinary syndrome of menopause is one of the most underdiagnosed and undertreated consequences of estrogen deficiency. Many women suffer in silence with painful sex, recurrent UTIs, and vaginal discomfort because they are too embarrassed to raise these symptoms, or because they have been told this is simply what aging looks like. Clinicians share the blame here: plenty of doctors hesitate to ask about sexual function, and plenty were never taught how to manage GSM once a patient does bring it up. That combination keeps a treatable condition invisible in the exam room.
What the Research Shows
This is a narrative review of the published literature on GSM, not a new clinical trial. The authors searched PubMed Central in July 2023 for studies on GSM, vulvovaginal atrophy, and urogenital atrophy in relation to quality of life and treatment, drawing on English-language articles published from 2002 onward.
The prevalence figures they report: GSM affects 40 to 54% of postmenopausal women and 15% of premenopausal women. Only a few of those women seek consultation, and around 60% of them have never received a diagnosis of GSM. The condition involves changes across the labia majora and minora, the introitus, the vagina, and the lower urinary tract. GSM is also seen in women receiving anti-estrogenic treatment for breast cancer, particularly aromatase inhibitors.
The authors describe GSM as progressive. They note that concern about menopause tends to begin with hot flashes and end with vaginal dryness, leaving the sexual health consequences and the psychological effects on self-image and relationships largely ignored. One study from a tertiary care hospital in Kathmandu found that vaginal symptoms mainly affect sexual health, with little effect on day-to-day activities. Of the available treatment options, the review identifies low-dose topical estrogen therapy as the most effective.
How This Works (Biological Rationale)
GSM arises from the hypoestrogenic state that follows menopause. Estrogen supports the urogenital tissues, and when circulating levels fall, the labia, introitus, vagina, and lower urinary tract all change. Because the lower urinary tract is estrogen-responsive along with the vaginal tissue, the same hormonal shift produces both the genital symptoms (dryness, irritation, burning, itching, abnormal discharge) and the urinary ones (urgency, frequency, discomfort with urination, incontinence, recurrent infections). That shared mechanism is why the older term vulvovaginal atrophy was replaced: it left out the urinary symptoms entirely and did not convey that the cause is estrogen loss.
Practical Takeaways
- Recognize that vaginal dryness, painful sex, and recurrent UTIs after menopause are symptoms of a treatable condition, not an inevitable part of aging
- Know that low-dose topical estrogen therapy is identified in this review as the most effective of the available treatment options
- Understand that GSM includes urinary symptoms, so urgency, frequency, and repeated infections belong in the same conversation as vaginal dryness
- Ask directly if your clinician does not raise the topic, since many providers hesitate to ask about sexual symptoms
- Raise it too if you are on anti-estrogenic therapy for breast cancer, especially an aromatase inhibitor, since GSM is seen in this group
- Do not wait for symptoms to become severe, because GSM is progressive rather than self-limiting
What This Means for Perimenopause and Menopause Care
This review makes the case that menopause care has to reach past hot flashes. With longer life expectancy, roughly one-third of a woman’s life is spent postmenopause, which puts a long horizon on conditions driven by low circulating estrogen. The authors argue for two changes: educating women so they know these symptoms are worth a consultation, and training clinicians to raise the subject, diagnose accurately, and tailor treatment to symptom severity and patient preference. They also flag how little research exists on the effects of GSM on women’s daily lives in the Indian context.
Related Studies and Research
- Recurrent Urinary Tract Infection in Older Outpatient Women
- Hormone therapy for sexual function in perimenopausal and postmenopausal women
- Effects of menopause on temperature regulation
- Sleep disturbance associated with the menopause
- Episode 27: Perimenopause, Menopause, and HRT - What Every Woman Should Know
FAQs
Is vaginal dryness after menopause normal?
It is common: this review puts GSM at 40 to 54% of postmenopausal women. Common is not the same as untreatable. GSM is a recognized medical condition with established treatment, and low-dose topical estrogen is the most effective option the authors identify.
Why did the name change from vulvovaginal atrophy to GSM?
The older term did not cover the urinary symptoms, incontinence, urgency, and discomfort, and it did not convey that the underlying cause is a hypoestrogenic state. GSM names both the full symptom range and the mechanism.
Will these symptoms get better on their own?
GSM is described in this review as a progressive condition.
Bottom Line
Genitourinary syndrome of menopause affects 40 to 54% of postmenopausal women and 15% of premenopausal women, yet around 60% of affected women have never been given the diagnosis. It is progressive, it reaches the urinary tract as well as the vagina, and low-dose topical estrogen therapy is the most effective treatment this review identifies. The barrier is largely a conversation that never happens, in both directions.
